The immunobiology and immunotherapy of ovarian cancer

Journal Article · Sat Jun 01 00:00:00 EDT 1991 · Seminars in Oncology; (United States)

OSTI ID:5265259

Bookman, M A; Bast, Jr, R C ^[1]

---

1. Fox Chase Cancer Center, Philadelphia, PA (USA)

Small volume residual peritoneal disease in patients undergoing therapy for ovarian carcinoma remains an attractive, but elusive, target for immunobiological therapy. Hypothetical advantages and disadvantages of regional peritoneal therapy are being better defined through increased clinical experience and more sophisticated animal models. Developments in cytokine biology, adoptive cellular therapy, monoclonal antibody conjugation, and molecular biology continue to provide an exciting, and nearly overwhelming, array of reagents for clinical evaluation. Ongoing and anticipated investigational trials should provide intriguing data in years to follow.198 references.

• OSTI ID: 5265259
• Journal Information: Seminars in Oncology; (United States), Journal Name: Seminars in Oncology; (United States) Vol. 18:3; ISSN SOLGA; ISSN 0093-7754
• Country of Publication: United States
• Language: English

Related Subjects

550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BODY
CARCINOMAS
DISEASES
FEMALE GENITALS
GONADS
GROWTH FACTORS
IMMUNOLOGY
IMMUNOTHERAPY
INTERFERON
LYMPHOKINES
MEDICINE
MITOGENS
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
OVARIES
PATIENTS
PROTEINS
RADIOIMMUNOLOGY
RADIOIMMUNOTHERAPY
RADIOLOGY
RADIOTHERAPY
THERAPY